A more accessible lower -risk polio vaccine is on the horizon, has found a research led by the University of Leeds.
Researchers have taken a significant step towards producing a more affordable vaccine and lower risk of vaccine using virus -type particles (VLPS). These particles mimic the outer protein shell of polio, but they are empty. This means that there is no risk of infection, but the VLP still causes the immune system to respond.
Now, a research program led by Professor David Rowlands, a peer professor of Molecular Iology at the University of Leeds, has tested the effectiveness of using different dough, insect, mammal and herbal cell cells as VLPs.
In a document published in Nature communicationsFindings show that VLPs produced in both dough cells and insect cells can perform equally or better than current inactivated polio vaccine (IPV), which creates an response to the immune system using a killed version of polio.
Professor Nicola Stonehouse is a chair in the Molecular Biology of the Linds University School of Molecular and Cell Biology and one of the highest authors on paper.
Professor Stonehouse said: “Any vaccine is just as effective as the number of children who arrive. The key is to make vaccines worldwide accessible, as all children have the right to protect themselves from diseases such as polio, no matter where they live. In the end, VLPs will make a significant contribution to the equality of the vaccine.
“Thanks to the research like this, we are already working with commercial partners to produce the next generation of polio vaccines. Although we do not yet know when they will be widely available, we are getting closer to a future without polio. ”
Today’s polio vaccines
Currently, IPV is relatively expensive for production because it requires high levels of bio-continent to minimize the risk of living polio leakage, which could lead to fireplaces. VLPs are non -infectious and would not have to be treated under such strict biodegradation conditions.
The oral polio vaccine (OPV), which contains a vibrant but impaired vaccine, is also used in vaccination against polio.
Future polio vaccines
However, when all other executives of wild polio have been successfully eliminated, the use of OPV will have to stop to eliminate a slight risk of circulation of the political variant that may be associated with its use.
In populations where a large number of people are not vaccinated and the disposal of sewage is poor, such strains can cause epidemic by contact with faeces, often through contaminated water.
Currently, IPV will be the only polio vaccine available to populations, but expensive production processes make it unaccounted for for countries with lower incomes.
Non -infectious VLPs are easier produced by current IPVs and research has shown that it is more stable temperature, thanks to the genetic deterioration of the external shell. As they are not infectious, this means that they will be less expensive for production, helping to improve the fair access to vaccination.
Dr. Martin Eisenhawer is the focus of the who for the development of VLP polio and the VLP consortium led by the University of Leeds. Dr. Eisenhawer said: “WHO, when considering research and development priorities for new generation polio vaccines, has early VLPs as a technology that could be an ideal tool, especially for the post -protection period with the aim of ultimately creating VLPs for the development of polio and polio, supply.
“Through an extensive cooperation with the research consortium, vaccine manufacturers and the global initiative to eliminate polio (GPEI), we approach this goal with new developments. This research shows that a critical new solution of polio vaccine is on the horizon. It would be a crucial new tool not only to achieve, but also to maintain the global elimination of polio and to ensure – in a fair way – that no child who will never be paralyzed again by any polio. This is to ensure that once polio will be eliminated, it will be eliminated. ”
International Research Cooperation, funded by the World Health Organization, also included researchers at the University of Oxford, the Drugs and Health and Health Organization (MHRA), the John Innes Center, the Pirbright Institute of Pirbright and the University of Florida. The building blocks were collected using a cold-electron microscope at the source of diamond light.
VLPS are already used in hepatitis B vaccines and human papillary (HPV) – and researchers have been working for over a decade to apply this successful technology to help eliminate polio.
The next generation of polio vaccinations is likely to be produced in dough or insect cells, as research has shown that they were effective when tested in rats and mice. These cellular expression systems are also favored by companies and are used for existing vaccinations due to their low costs.
Dr. Lee Sherry was one of the four authors of the paper while working at the University of Leeds. Dr. Sherry, who now holds a position at the University of Glasgow, said: “After the success of the use of VLP vaccines to prevent diseases associated with hepatitis B and HPV. It is very exciting to see this research promoted by industrial partners as a safer vaccine production strategy as we move towards a world without polio. ”
More information
Recomplete expression systems to produce stabilized particles that look like a virus -like polio vaccines were published Nature communications (open access). The research program was guided by Professor David Rowlands at the University of Leeds. The first authors are Lee Sherry (University of Glasgow, former University of Leeds), Mohammad W. Bahar (University of Oxford), Claudine Porta (University of Oxford) and Helen Fox (MHRA).
Source:
Magazine report:
Sherry, L., et al. (2025). Recompactive expression systems for the production of stabilized particles that look like viruses as a next -generation polio vaccines. Nature communications. Doi.org/10.1038/S41467-025-56118-Z.
